Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • PostDoc Fellow Urology/Cell Biology, Surgery, Baylor College of Medicine 1994 - 1997
  • Urologic Surgery Resident, Surgery, Duke University 1990 - 1994
  • Urologic Surgery Fellow, Surgery, Duke University 1989 - 1990
  • General Surgery Intern, Surgery, University of Michigan at Ann Arbor 1987 - 1989
  • M.D., University of Michigan at Ann Arbor 1987
  • B.A., Spring Arbor University 1983
• 

  Medical Licensure

  • 421293. Pennsylvania. 2003
  • 33828. North Carolina. 1991
• 

  Duke Appointment History

  • Instructor in the Department of Surgery, Surgery, Urology, Surgery 2018
• 

  Academic Positions Outside Duke

  • Associate Professor Urology, University of Pittsburgh. 2003 - 2018
  • Associate Professor of Urology, University of Tennessee. 2001 - 2003
  • Assistant Professor of Urology, University of Tennessee. 1997 - 2001
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Lee, AJ, Yabes, JG, Hale, N, Hrebinko, RL, Gingrich, JR, Maranchie, JK, Fam, MM, Turner I I, RM, Davies, BJ, Ben-David, B, and Jacobs, BL. "The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients." The Canadian Journal of Urology 25, no. 2 (April 2018): 9255-9261..
    • Maganty, A, Fombona, A, Bandari, J, Lyon, TD, Kulich, S, Gingrich, JR, Bigley, JD, and Tarin, TV. "Aggressive surgical management of adenocarcinoma of the rete testis." Urology Case Reports 16 (January 1, 2018): 72-74.  Full Text
    • Tyagi, P, Motley, SS, Koyama, T, Kashyap, M, Gingrich, J, Yoshimura, N, and Fowke, JH. "Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients." The Prostate 78, no. 1 (January 2018): 17-24.  Full Text
    • Lyon, TD, Turner I I, RM, McBride, D, Wang, L, Gingrich, JR, Hrebinko, RL, Jacobs, BL, Davies, BJ, and Tarin, TV. "Preoperative immunonutrition prior to radical cystectomy: a pilot study." The Canadian Journal of Urology 24, no. 4 (August 2017): 8895-8901.
    • Skolarus, TA, Metreger, T, Hwang, S, Kim, HM, Grubb, RL, Gingrich, JR, and Hawley, ST. "Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial." Trials 18, no. 1 (April 18, 2017): 181-null.  Full Text
    • Tyagi, P, Motley, SS, Kashyap, M, Pore, S, Gingrich, J, Wang, Z, Yoshimura, N, and Fowke, JH. "Urine chemokines indicate pathogenic association of obesity with BPH/LUTS." International Urology and Nephrology 47, no. 7 (July 2015): 1051-1058.  Full Text
    • Kashyap, M, Pore, S, Wang, Z, Gingrich, J, Yoshimura, N, and Tyagi, P. "Inflammasomes are important mediators of prostatic inflammation associated with BPH." Journal of Inflammation (United Kingdom) 12, no. 1 (May 17, 2015).  Full Text
    • Pascal, LE, Masoodi, KZ, O'Malley, KJ, Shevrin, D, Gingrich, JR, Parikh, RA, and Wang, Z. "5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy." The Journal of Urology 193, no. 4 (April 2015): 1388-1393.  Full Text
    • Muthuswamy, R, Wang, L, Pitteroff, J, Gingrich, JR, and Kalinski, P. "Combination of IFNα and poly-I: C reprograms bladder cancer microenvironment for enhanced CTL attraction." Journal for Immunotherapy of Cancer 3, no. 1 (March 24, 2015).  Full Text
    • Funahashi, Y, Wang, Z, O'Malley, KJ, Tyagi, P, DeFranco, DB, Gingrich, JR, Takahashi, R, Majima, T, Gotoh, M, and Yoshimura, N. "Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats." The Prostate 75, no. 4 (March 2015): 381-389.  Full Text
    • Correa, AF, Theisen, K, Ferroni, M, Maranchie, JK, Hrebinko, R, Davies, BJ, and Gingrich, JR. "The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer." Advances in Urology 2015 (January 1, 2015).  Full Text
    • Kalinski, P, and Gingrich, JR. "Toward improved effectiveness of bladder cancer immunotherapy." Immunotherapy 7, no. 10 (January 2015): 1039-1042.  Full Text
    • Lyon, TD, Farber, NJ, Chen, LC, Fuller, TW, Davies, BJ, Gingrich, JR, Hrebinko, RL, Maranchie, JK, Taylor, JM, and Tarin, TV. "Total Psoas Area Predicts Complications following Radical Cystectomy." Advances in Urology 2015 (January 1, 2015).  Full Text
    • "Comprehensive molecular characterization of urothelial bladder carcinoma." Nature 507, no. 7492 (March 2014): 315-322.  Full Text
    • Armstrong, AJ, Häggman, M, Stadler, WM, Gingrich, JR, Assikis, V, Polikoff, J, Damber, JE, Belkoff, L, Nordle, Ö, Forsberg, G, Carducci, MA, and Pili, R. "Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 19, no. 24 (December 2013): 6891-6901.  Full Text
    • Lotan, Y, Amiel, G, Boorjian, SA, Clark, PE, Droller, M, Gingrich, JR, Guzzo, TJ, Inman, BA, Kamat, AM, Karsh, L, Nielsen, ME, Smith, ND, Shariat, SF, Svatek, RS, Taylor, JM, Bladder Cancer Think Tank, , and Bladder Cancer Advocacy Network, . "Comprehensive handbook for developing a bladder cancer cystectomy database." Urologic Oncology 31, no. 6 (August 2013): 812-826.  Full Text
    • He, W, Li, X, Xu, S, Ai, J, Gong, Y, Gregg, JL, Guan, R, Qiu, W, Xin, D, Gingrich, JR, Guo, Y, and Chang, G. "Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression." Biochemical and Biophysical Research Communications 435, no. 4 (June 2013): 526-532.  Full Text
    • Knowles, LM, Zewe, J, Malik, G, Parwani, AV, Gingrich, JR, and Pilch, J. "CLT1 targets bladder cancer through integrin α5β1 and CLIC3." Molecular Cancer Research : Mcr 11, no. 2 (February 2013): 194-203.  Full Text
    • Wilt, TJ, Brawer, MK, Jones, KM, Barry, MJ, Aronson, WJ, Fox, S, Gingrich, JR, Wei, JT, Gilhooly, P, Grob, BM, Nsouli, I, Iyer, P, Cartagena, R, Snider, G, Roehrborn, C, Sharifi, R, Blank, W, Pandya, P, Andriole, GL, Culkin, D, and Wheeler, T. "Radical prostatectomy versus observation for localized prostate cancer." New England Journal of Medicine 367, no. 3 (July 19, 2012): 203-213.  Full Text
    • Armstrong, AJ, Gingrich, JR, Haggman, M, Stadler, WM, Damber, JE, Belkoff, L, Clark, R, Brosman, S, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer." European Urology Supplements 11, no. 1 (February 1, 2012): E126-U515.  Link to Item
    • Pili, R, Häggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Björk, A, Nordle, O, Forsberg, G, Carducci, MA, and Armstrong, AJ. "Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 30 (October 2011): 4022-4028.  Full Text
    • Chen, L, Fang, B, Giorgianni, F, Gingrich, JR, and Beranova-Giorgianni, S. "Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis." Electrophoresis 32, no. 15 (August 2011): 1984-1991.  Full Text
    • Gingrich, JR. "Bladder cancer: chemohyperthermia for bladder cancer--clinically effective?." Nature Reviews. Urology 8, no. 8 (July 19, 2011): 414-416.  Full Text
    • Armstrong, AJ, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 126-126.  Full Text
    • Armstrong, AJ, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011): 126-null.
    • Chang, G, Xu, S, Dhir, R, Chandran, U, O'Keefe, DS, Greenberg, NM, and Gingrich, JR. "Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 16, no. 22 (November 9, 2010): 5390-5401.  Full Text
    • Corcoran, AT, and Gingrich, JR. "Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?." Oncology (Williston Park, N.Y.) 24, no. 12 (November 2010): 1161-1166.
    • Smaldone, MC, and Gingrich, JR. "Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer." Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology 62, no. 2 (June 2010): 129-132.
    • Pili, R, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Bjork, A, Forsberg, G, Carducci, MA, and Armstrong, AJ. "A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)." Journal of Clinical Oncology 28, no. 15 (May 20, 2010).  Link to Item
    • Chang, G, Xu, S, Watanabe, M, Jayakar, HR, Whitt, MA, and Gingrich, JR. "Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer." The Journal of Urology 183, no. 4 (April 2010): 1611-1618.  Full Text
    • Smaldone, MC, Casella, DP, Welchons, DR, and Gingrich, JR. "Investigational therapies for non-muscle invasive bladder cancer." Expert Opinion on Investigational Drugs 19, no. 3 (March 2010): 371-383. (Review)  Full Text
    • Smaldone, MC, Gayed, BA, Tomaszewski, JJ, and Gingrich, JR. "Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer." Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology 61, no. 2 (June 2009): 71-89. (Review)
    • Wilt, TJ, Brawer, MK, Barry, MJ, Jones, KM, Kwon, Y, Gingrich, JR, Aronson, WJ, Nsouli, I, Iyer, P, Cartagena, R, Snider, G, Roehrborn, C, and Fox, S. "The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer." Contemporary Clinical Trials 30, no. 1 (January 2009): 81-87.  Full Text
    • Chikwava, KR, Gingrich, JR, and Parwani, AV. "Lymphoepithelioma-like carcinoma of the urinary bladder." Pathology 40, no. 3 (April 2008): 310-311. (Letter)  Full Text
    • Xiao, W, Zhang, Q, Habermacher, G, Yang, X, Zhang, A-Y, Cai, X, Hahn, J, Liu, J, Pins, M, Doglio, L, Dhir, R, Gingrich, J, and Wang, Z. "U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia." Oncogene 27, no. 11 (March 2008): 1536-1544.  Full Text
    • Hernandez, I, Maddison, LA, Wei, Y, DeMayo, F, Petras, T, Li, B, Gingrich, JR, Rosen, JM, and Greenberg, NM. "Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival." Molecular Cancer Research : Mcr 1, no. 14 (December 2003): 1036-1047.
    • Hale, GA, Rochester, RJ, Heslop, HE, Krance, RA, Gingrich, JR, Benaim, E, Horwitz, EM, Cunningham, JM, Tong, X, Srivastava, DK, Leung, WH, Woodard, P, Bowman, LC, and Handgretinger, R. "Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 9, no. 11 (November 2003): 698-705.  Full Text
    • Foster, BA, Evangelou, A, Gingrich, JR, Kaplan, PJ, DeMayo, F, and Greenberg, NM. "Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice." Differentiation; Research in Biological Diversity 70, no. 9-10 (December 2002): 624-632.  Full Text
    • Lin, X, Gingrich, JR, Bao, W, Li, J, Haroon, ZA, and Demark-Wahnefried, W. "Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice." Urology 60, no. 5 (November 2002): 919-924.  Full Text
    • Steiner, MS, Gingrich, JR, and Chauhan, RD. "Prostate cancer gene therapy." Surgical Oncology Clinics of North America 11, no. 3 (July 2002): 607-620. (Review)  Full Text
    • Weld, KJ, Mayher, BE, Allay, JA, Cockroft, JL, Reed, CP, Randolph, MM, Lu, Y, Steiner, MS, and Gingrich, JR. "Transrectal gene therapy of the prostate in the canine model." Cancer Gene Therapy 9, no. 2 (February 2002): 189-196.  Full Text
    • Blankenship, JC, Gavant, ML, Cox, CE, Chauhan, RD, and Gingrich, JR. "Importance of delayed imaging for blunt renal trauma." World Journal of Surgery 25, no. 12 (December 2001): 1561-1564.  Full Text
    • Gingrich, JR, Chauhan, RD, and Steiner, MS. "Gene therapy for prostate cancer." Current Oncology Reports 3, no. 5 (September 2001): 438-447. (Review)  Full Text
    • Chauhan, RD, Gingrich, JR, Eltorky, M, and Steiner, MS. "The natural progression of adenocarcinoma of the epididymis." The Journal of Urology 166, no. 2 (August 2001): 608-610.  Full Text
    • Gingrich, JR, Chauhan, RD, and Steiner, MS. "Gene therapy for prostate cancer." Current Urology Reports 2, no. 3 (June 2001): 199-208. (Review)  Full Text
    • Mayher, BE, Guyton, JL, and Gingrich, JR. "Impact of urethral injury management on the treatment and outcome of concurrent pelvic fractures." Urology 57, no. 3 (March 2001): 439-442.  Full Text
    • Bruckheimer, EM, Brisbay, S, Johnson, DJ, Gingrich, JR, Greenberg, N, and McDonnell, TJ. "Bcl-2 accelerates multistep prostate carcinogenesis in vivo." Oncogene 19, no. 46 (November 2000): 5251-5258.  Full Text
    • Steiner, MS, and Gingrich, JR. "Gene therapy for prostate cancer: where are we now?." The Journal of Urology 164, no. 4 (October 2000): 1121-1136. (Review)  Full Text
    • Bruckheimer, EM, Cho, S, Brisbay, S, Johnson, DJ, Gingrich, JR, Greenberg, N, and McDonnell, TJ. "The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo." Oncogene 19, no. 20 (May 2000): 2404-2412.  Full Text
    • Gingrich, JR, and Steiner, MS. "Gene therapy in urologic oncology." World Journal of Urology 18, no. 2 (April 2000): 91-92.  Full Text
    • Strong, C, Gingrich, JR, and Kutteh, WH. "Ethics of postmortem sperm retrieval: ethics of sperm retrieval after death or persistent vegetative state." Human Reproduction (Oxford, England) 15, no. 4 (April 2000): 739-745.  Full Text
    • McCarville, MB, Hoffer, FA, Gingrich, JR, and Jenkins, JJ. "Imaging findings of hemorrhagic cystitis in pediatric oncology patients." Pediatric Radiology 30, no. 3 (March 2000): 131-138. (Review)  Full Text
    • Gingrich, JR. "Erratum: C-CAM adhesion in mouse model (Journal of Urology 162:3 (892))." Journal of Urology 163, no. 1 (January 1, 2000): 253-null.
    • Gingrich, JR, Barrios, RJ, Foster, BA, and Greenberg, NM. "Pathologic progression of autochthonous prostate cancer in the TRAMP model." Prostate Cancer and Prostatic Diseases 2, no. 2 (January 1, 1999): 70-75.  Full Text
    • Gingrich, JR, and Steiner, MS. "A gene hunting we will go!." Urological Research 26, no. 6 (January 1998): 361-369. (Review)  Full Text
    • Gingrich, JR, Barrios, RJ, Kattan, MW, Nahm, HS, Finegold, MJ, and Greenberg, NM. "Androgen-independent prostate cancer progression in the TRAMP model." Cancer Research 57, no. 21 (November 1997): 4687-4691.
    • Foster, BA, Gingrich, JR, Kwon, ED, Madias, C, and Greenberg, NM. "Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model." Cancer Research 57, no. 16 (August 1997): 3325-3330.
    • Gingrich, JR, Barrios, RJ, Morton, RA, Boyce, BF, DeMayo, FJ, Finegold, MJ, Angelopoulou, R, Rosen, JM, and Greenberg, NM. "Metastatic prostate cancer in a transgenic mouse." Cancer Research 56, no. 18 (September 1996): 4096-4102.
    • Gingrich, JR, and Greenberg, NM. "A transgenic mouse prostate cancer model." Toxicologic Pathology 24, no. 4 (July 1996): 502-504.  Full Text
    • Gingrich, JR, and Paulson, DF. "The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?." Surgical Oncology Clinics of North America 4, no. 2 (April 1995): 335-344. (Review)  Full Text
    • Keane, TE, Gingrich, JR, Rosner, G, Webb, KS, Poulton, SH, and Walther, PJ. "Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model." Cancer Research 54, no. 2 (January 1994): 475-481.
    • Keane, TE, Rosner, GL, Gingrich, JR, Poulton, SH, and Walther, PJ. "The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer." The Journal of Urology 146, no. 5 (November 1991): 1418-1424.  Full Text
    • Gingrich, JR, Tucker, JA, Walther, PJ, Day, JW, Poulton, SH, and Webb, KS. "Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1)." The Journal of Urology 146, no. 3 (September 1991): 915-919.  Full Text
    • Keane, TE, Gingrich, JR, Rosner, G, and Walther, PJ. "Preclinical in vivo assessment of 5-fluorouracil/cisplatin with and without dipyridamole against a human bladder tumor line: Correlation of tumor growth inhibition with host survival." Surgical Forum 41 (December 1, 1990): 696-698.

  • Conference Papers

    • Carducci, M, Armstrong, A, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, V, Forsberg, G, Olsson, A, Nordle, O, and Pili, R. "TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL." 37th Congress of the European-Society-for-Medical-Oncology (ESMO). Vienna, AUSTRIA. September 28, 2012 - October 2, 2012.: OXFORD UNIV PRESS, September 1, 2012.  Link to Item
    • Armstrong, AJ, Haggman, M, Stadler, WM, Gingrich, JR, Assikis, VJ, Polikoff, J, Denmeade, SR, George, DJ, Andreou, C, Clark, WR, Sieber, P, Agajanian, R, Belkoff, L, Damber, J-E, Nordle, O, Forsberg, G, Carducci, MA, and Pili, R. "Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 1, 2012 - June 6, 2012.: AMER SOC CLINICAL ONCOLOGY, May 20, 2012.  Link to Item
    • Giorgianni, F, Gingrich, JR, Steiner, MS, Desiderio, DM, and Beranova-Giorgianni, S. "Analysis of the proteome in the human prostate." December 1, 2002.
• Scholarly, Clinical, & Service Activities
• 

  Academic & Administrative Activities

  • Chief of Urology at the Durham VA Health Care System.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.